Sandro Wealth Management LLC Purchases Shares of 3,928 Thermo Fisher Scientific Inc. $TMO

Key Points

• Sandro Wealth Management acquired 3,928 Thermo Fisher Scientific shares valued at approximately $1.97 million, making TMO 1.4% of its portfolio. Institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly adjusted EPS of $6.03 and revenue of $11.99 billion, beating estimates of $5.71 and $11.71 billion, respectively; revenue increased 10.5% year over year.
• Analysts rate TMO a “Moderate Buy” with an average price target of $619.41, while the company declared a quarterly dividend of $0.47 per share, representing a 0.3% yield.

Sandro Wealth Management LLC acquired a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm acquired 3,928 shares of the medical research company's stock, valued at approximately $1,969,000. Thermo Fisher Scientific accounts for about 1.4% of Sandro Wealth Management LLC's holdings, making the stock its 23rd biggest position.

A number of other institutional investors also recently modified their holdings of TMO. J. Stern & Co. LLP grew its holdings in Thermo Fisher Scientific by 58,006.4% in the fourth quarter. J. Stern & Co. LLP now owns 31,509,332 shares of the medical research company's stock worth $18,258,082,000 after purchasing an additional 31,455,105 shares during the period. Norges Bank acquired a new stake in shares of Thermo Fisher Scientific in the 4th quarter valued at about $3,072,744,000. Auto Owners Insurance Co raised its stake in Thermo Fisher Scientific by 57,845.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,427,896 shares of the medical research company's stock worth $1,406,844,000 after buying an additional 2,423,706 shares during the period. T. Rowe Price Investment Management Inc. grew its stake in Thermo Fisher Scientific by 2,183.2% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 1,328,845 shares of the medical research company's stock valued at $770,000,000 after acquiring an additional 1,270,643 shares during the period. Finally, Price T Rowe Associates Inc. MD raised its position in shares of Thermo Fisher Scientific by 19.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 7,701,353 shares of the medical research company's stock worth $4,462,550,000 after purchasing an additional 1,230,872 shares during the period. Institutional investors and hedge funds own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Shares of TMO opened at $586.62 on Tuesday. The stock has a 50 day moving average of $531.72 and a 200 day moving average of $508.48. The company has a current ratio of 1.55, a quick ratio of 1.18 and a debt-to-equity ratio of 0.74. Thermo Fisher Scientific Inc. has a 12 month low of $435.27 and a 12 month high of $643.99. The company has a market capitalization of $216.90 billion, a price-to-earnings ratio of 31.56, a PEG ratio of 2.39 and a beta of 0.84.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last announced its earnings results on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.71 by $0.32. The firm had revenue of $11.99 billion during the quarter, compared to analyst estimates of $11.71 billion. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business's revenue was up 10.5% compared to the same quarter last year. During the same period last year, the firm posted $4.28 EPS. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. As a group, sell-side analysts forecast that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current year.

Thermo Fisher Scientific Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. The ex-dividend date is Tuesday, September 15th. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. Thermo Fisher Scientific's dividend payout ratio (DPR) is presently 10.11%.

Wall Street Analysts Forecast Growth

TMO has been the subject of several research reports. Piper Sandler lifted their price target on shares of Thermo Fisher Scientific from $510.00 to $600.00 and gave the company a "neutral" rating in a research report on Monday, July 27th. Royal Bank Of Canada lifted their price objective on shares of Thermo Fisher Scientific from $490.00 to $580.00 and gave the company a "sector perform" rating in a report on Friday, July 24th. Morgan Stanley raised their price target on shares of Thermo Fisher Scientific from $620.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. Wolfe Research started coverage on Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price objective for the company. Finally, Barclays lifted their target price on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an "overweight" rating in a research report on Friday, July 24th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and an average target price of $619.41.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 420 shares of Thermo Fisher Scientific stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the completion of the transaction, the chief accounting officer owned 2,966 shares in the company, valued at $1,734,546.46. This trade represents a 12.40% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael D. Shafer sold 25,500 shares of Thermo Fisher Scientific stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $600.00, for a total transaction of $15,300,000.00. Following the completion of the transaction, the executive vice president owned 20,994 shares of the company's stock, valued at $12,596,400. This represents a 54.85% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 52,053 shares of company stock valued at $30,643,589 in the last quarter. 0.33% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source